GlassScriptPhysician profile
Syed Gilani
NPI 1447451182
$4,541.44
in general payments reported to CMS, 2019-2025
22 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $57.00 · 2021: $221 · 2022: $1,088 · 2023: $1,616 · 2024: $356 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956 · Travel and Lodging: $826 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.29 |
| Travel and Lodging | $825.60 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $825.60 | 2025 | Thermocool Sf |
| Genzyme Corporation | $601.46 | 2019-2023 | |
| Insmed, INC. | $496.60 | 2019-2024 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $381.68 | 2020-2023 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $363.41 | 2022-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $273.18 | 2022-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $259.30 | 2019-2023 | Opsumit, Uptravi |
| Abbvie INC. | $191.53 | 2024 | |
| Gilead Sciences, INC. | $173.15 | 2023-2024 | Veklury |
| Baxter Healthcare | $170.76 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.38 | 2022-2023 | Ofev |
| Jazz Pharmaceuticals INC. | $125.00 | 2021 | |
| Merck Sharp & Dohme LLC | $92.28 | 2022-2023 | Recarbrio, Zerbaxa, Dificid |
| Novartis Pharmaceuticals Corporation | $85.13 | 2022-2023 | |
| Philips North America LLC | $69.37 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $66.21 | 2023 | Yupelri |
| Amgen INC. | $52.08 | 2022-2023 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $48.20 | 2023 | Glassia |
| Genentech USA, INC. | $47.73 | 2022-2023 | Xolair |
| Astellas Pharma US INC | $37.17 | 2023 | Cresemba |
| Paratek Pharmaceuticals, INC. | $19.54 | 2023 | Nuzyra |
| La Jolla Pharmaceutical Company | $14.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Gilani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.